BioSpace News Archive

Genetown

Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease

Sosei Group Corporation announces it has initiated discussions with GSK to regain full ownership of GSK4381406, a highly selective first-in-class, oral GPR35 agonist in development under a Global Collaboration and License Agreement with GSK as a potential new treatment for Inflammatory Bowel Diseases.

November 24, 2023
·
7 min read
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation Award

Theratechnologies Inc. today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (formerly known as the Québec Consortium for Drug Discovery) and the Association for the Development of Research and Innovation of Québec (ADRIQ).

November 24, 2023
·
7 min read
Business

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

Anavex Life Sciences Corp. today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023.

November 24, 2023
·
3 min read
Deals

Protect Pharmaceutical Corp. Acquires Bosfor Export

Protect Pharmaceutical Corp. “OTC: PRTT” is pleased to announce the acquisition of Bosfor Export.

November 24, 2023
·
1 min read
Drug Development

Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and CAN10

Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data providing further support for its lead assets, the IL1RAP-binding antibodies nadunolimab (CAN04) and CAN10, in both cancer and cardiovascular disease.

November 24, 2023
·
4 min read
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy

Calliditas Therapeutics AB announced that its partner Everest Medicines announced that China’s National Medical Products Administration has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression.

November 24, 2023
·
2 min read
Business

Biovica International’s Invitation to Webcast for Q2 2023/2024

Biovica International publishes its interim report for the second quarter 2023/2024, on November 28 at 08:00 CET.

November 24, 2023
·
1 min read
STEMCELL Technologies Wins a Canada’s Most Admired Corporate Cultures™ of 2023 Award

STEMCELL Technologies, Canada’s largest biotechnology company, has received the Canada’s Most Admired Corporate Cultures™ of 2023 award by Waterstone Human Capital.

November 24, 2023
·
3 min read